--- canonical_url: https://www.stockexpertai.com/earnings/abt last_updated: 2026-05-03T21:19:36.033Z --- # Abbott Laboratories (ABT) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-03T21:19:34.850Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $89.47 (▼ -1.45%) | fmp:quote | | Market Cap | $155.5B | fmp:profile | | 52w range | $89.14 – $139.06 | fmp:quote | | Earnings | Thu 16 Jul | fmp:earnings-history | | EPS estimate | $1.28 (+2% YoY) | fmp:earnings-estimate | | Revenue estimate | $12.5B | fmp:earnings-estimate | | Beat streak | 1/4 | fmp:earnings-history | | Rating | B (overall 3/5) | fmp:ratings | | Analyst median target | $125 (+39.7% upside) | fmp:price-target-consensus | | MoonshotScore | 50/100 | derived | | Council | 5/6 bullish | derived | | Munger verdict | Undervalued | derived | ## Abbott Laboratories — Q4 FY2026 Expectations Q4 consensus: revenue $12.5B^{[FMP est]}, EPS $1.28^{[FMP est]}. 1 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B · **Stance:** BUY · **Council:** 5/6 · **Moonshot:** 50 = MoonshotScore 50^{[9-pillar formula]} + Council 5/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (5 metrics) ### 1. Comparable Sales Growth Outlook Abbott's full-year 2026 sales growth outlook is 6.5% to 7.5%, which includes the full-year sales of Exact Sciences. > "To align with our reporting of comparable sales growth, our full-year 2026 sales growth outlook of 6.5% to 7.5% is now on a comparable basis as well. The sales growth outlook includes the full-year sales of Exact Sciences in both the prior and current year." > — Philip Boudreau, Executive Vice President, Finance and Chief Financial Officer, Expectation / Guide · Q1 FY2026 ### 2. Electrophysiology Growth Abbott expects growth in Electrophysiology, with 14% growth in the U.S. due to the launch of the Volt PFA catheter and double-digit growth in Europe due to the launch of the TactiFlex Duo catheter. > "In Electrophysiology, growth of 13% included contributions from two pulsed field ablation catheter launches in the quarter. The launch of our Volt PFA catheter contributed to growth of 14% in the U.S., and the launch of our TactiFlex Duo catheter helped drive mid-teens growth in Europe." > — Robert Ford, Chairman and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 3. Earnings Per Share Dilution Abbott's new guidance range midpoint of $5.48 for full-year adjusted earnings per share reflects $0.20 of dilution related to the Exact Sciences acquisition, compared to the previous guidance range midpoint of $5.68. > "Compared to our previous full-year adjusted earnings per share guidance range midpoint of $5.68, our new guidance range midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences acquisition, consistent with our assumption at the time of the announced transaction." > — Philip Boudreau, Executive Vice President, Finance and Chief Financial Officer, Investor Focus · Q1 FY2026 ### 4. Exact Sciences Acquisition The acquisition of Exact Sciences is forecasted to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott Laboratories' long-term sales growth rate. > "As we communicated at the time of the acquisition announcement, we forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott Laboratories' long-term sales growth rate." > — Robert Ford, Chairman and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 5. Rhythm Management Outperformance Abbott's Rhythm Management sales grew 13%, marking the third consecutive quarter of double-digit growth and continued outperforming the market significantly. > "In Rhythm Management, sales grew 13%, marking the third consecutive quarter that we have delivered double-digit growth and continued our track record of significantly outperforming the market." > — Robert Ford, Chairman and Chief Executive Officer, Management Quote · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 0.0 | weak | Q1 vs Q2: growth slowing (+0.2%, below threshold) | | Gross Margin | 6.0 | medium | Q1: high margin (56.3%) | | Operating Leverage | 2.0 | weak | op margin healthy (16.5%) | | Cash Runway | 10.0 | strong | FCF very strong ($0.9B, 2.3× CapEx) | | R&D Intensity | 5.0 | medium | average R&D (6.7%) | | Price Momentum | 4.0 | medium | RSI 27.6 oversold, 50d below | | News Sentiment | 8.0 | strong | strong buy consensus (75%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +39.7% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | bull | quant · RSI 28 | | Klarman | bull | value · target upside +39.7% | | Buffett | bull | quality · ROE score 4/5 | | Munger | bull | valuation · target upside +39.7% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Undervalued - **Financial Health:** Moderate - **Margin of Safety:** Strong - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 27.6 — oversold (RSI 27.6) — tepki alımı potansiyeli - **50d MA:** $104 — hisse %14.0 altında — kısa vadeli direnç - **200d MA:** $121 — hisse %25.8 altında — uzun vadeli baskı - **Volume (10d):** -3% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $1.26 | $1.26 | MISS | +2.6% | | Q3 FY25 | $1.30 | $1.30 | MISS | -1.4% | | Q4 FY25 | $1.50 | $1.50 | MISS | -1.1% | | Q1 FY26 | $1.15 | $1.14 | +0.9% EPS | +1.4% | Q1 (April 16, 2026): EPS $1.15 vs $1.14 est^[FMP], +0.9% beat. D+1 movement: +1.4%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $1.28 + CapEx discipline** Threshold: EPS > $1.28^{[FMP est]}. Target: Break above median target $125^{[FMP target]}; high target $152^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $1.28 + CapEx < $399.0M** Threshold: EPS ≈ $1.28^{[FMP est]}, Q4 CapEx < $399.0M^[FMP]. Target: Consolidation in the band between current $89^[FMP] and median $125^[FMP]. ### Scenario C · Miss **EPS < $1.24 or CapEx ≥ $399.0M** Threshold: EPS < $1.24^{[FMP est×0.97]}. Target: Current $89 below SMA200 $121^[FMP], if rejection continues, $102^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $1.15 vs $1.14 beat^[FMP], stock +1.4% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $399.0M^{[FMP cashflow]}. Q1 op margin 16.5%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $125 (+39.7% upside vs current $89) - **High / Low:** $152 / $92 - **Buy / Hold / Sell:** 21 / 7 / 0 - **Analyst count:** 7 (last quarter), 70 all-time ## Additional Transcript Insights ### 1. exact_sciences_acquisition **Claim:** The acquisition of Exact Sciences is forecasted to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott Laboratories' long-term sales growth rate. **Evidence (transcript):** "As we communicated at the time of the acquisition announcement, we forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott Laboratories' long-term sales growth rate." **Numbers:** $3 billion, 2026 ### 2. comparable_sales_growth_outlook **Claim:** Abbott's full-year 2026 sales growth outlook is 6.5% to 7.5%, which includes the full-year sales of Exact Sciences. **Evidence (transcript):** "To align with our reporting of comparable sales growth, our full-year 2026 sales growth outlook of 6.5% to 7.5% is now on a comparable basis as well. The sales growth outlook includes the full-year sales of Exact Sciences in both the prior and current year." **Numbers:** 6.5%, 7.5%, 2026 ### 3. earnings_per_share_dilution **Claim:** Abbott's new guidance range midpoint of $5.48 for full-year adjusted earnings per share reflects $0.20 of dilution related to the Exact Sciences acquisition, compared to the previous guidance range midpoint of $5.68. **Evidence (transcript):** "Compared to our previous full-year adjusted earnings per share guidance range midpoint of $5.68, our new guidance range midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences acquisition, consistent with our assumption at the time of the announced transaction." **Numbers:** $5.68, $5.48, $0.20 ### 4. electrophysiology_growth **Claim:** Abbott expects growth in Electrophysiology, with 14% growth in the U.S. due to the launch of the Volt PFA catheter and double-digit growth in Europe due to the launch of the TactiFlex Duo catheter. **Evidence (transcript):** "In Electrophysiology, growth of 13% included contributions from two pulsed field ablation catheter launches in the quarter. The launch of our Volt PFA catheter contributed to growth of 14% in the U.S., and the launch of our TactiFlex Duo catheter helped drive mid-teens growth in Europe." **Numbers:** 13%, 14% ### 5. rhythm_management_outperformance **Claim:** Abbott's Rhythm Management sales grew 13%, marking the third consecutive quarter of double-digit growth and continued outperforming the market significantly. **Evidence (transcript):** "In Rhythm Management, sales grew 13%, marking the third consecutive quarter that we have delivered double-digit growth and continued our track record of significantly outperforming the market." **Numbers:** 13% ### 6. diabetes_care_growth_outlook **Claim:** Abbott expects CGM to return to double-digit growth in the second quarter, despite the impact from a delay in the renewal process related to an international tender. **Evidence (transcript):** "As we look forward to the second quarter, we expect CGM to return to double-digit growth." **Numbers:** — --- *Data source: FMP (live query, 2026-05-03), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*